Gunnel Hellgren1,2, Chatarina Löfqvist2, Anna-Lena Hård2, Ingrid Hansen-Pupp3, Magnus Gram4, David Ley3, Lois E Smith5, Ann Hellström2. 1. Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 2. Department of Ophthalmology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 3. Department of Pediatrics, Institute of Clinical Sciences Lund, Lund University and Skane University Hospital, Lund, Sweden. 4. Department of Clinical Sciences, Institute of Clinical Sciences Lund, Lund University, Lund, Sweden. 5. Department of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND: The role of vascular endothelial growth factor (VEGF) in the pathogenesis of retinopathy of prematurity (ROP) has been clearly established. However, little is known about temporal changes in circulating VEGF concentrations in the preterm infant. The objective was to determine the longitudinal serum concentrations of VEGF in relation to ROP. METHODS: This study included 52 infants born at <31 wk gestational age (non-ROP n = 33, nonproliferative ROP n = 10, treated for ROP n = 9). VEGF concentrations were analyzed in blood samples collected at birth, at 3 d postnatal age, and then weekly until at least a gestational age of 35 wk. RESULTS: VEGF concentrations at birth did not differ between groups, independent of later ROP status. In contrast, VEGF serum concentrations were significantly higher at first detection of ROP in infants who were later treated for ROP compared to infants without ROP. At the time of laser therapy, serum VEGF concentrations did not differ between groups. CONCLUSION: Circulatory concentrations of VEGF, in infants who later developed severe ROP, were elevated at the time when ROP first was detected but not at the time when current treatment most often occurred. This supports the need for further studies of circulating VEGF in relation to the timing of ROP treatment.
BACKGROUND: The role of vascular endothelial growth factor (VEGF) in the pathogenesis of retinopathy of prematurity (ROP) has been clearly established. However, little is known about temporal changes in circulating VEGF concentrations in the preterm infant. The objective was to determine the longitudinal serum concentrations of VEGF in relation to ROP. METHODS: This study included 52 infants born at <31 wk gestational age (non-ROP n = 33, nonproliferative ROP n = 10, treated for ROP n = 9). VEGF concentrations were analyzed in blood samples collected at birth, at 3 d postnatal age, and then weekly until at least a gestational age of 35 wk. RESULTS:VEGF concentrations at birth did not differ between groups, independent of later ROP status. In contrast, VEGF serum concentrations were significantly higher at first detection of ROP in infants who were later treated for ROP compared to infants without ROP. At the time of laser therapy, serum VEGF concentrations did not differ between groups. CONCLUSION: Circulatory concentrations of VEGF, in infants who later developed severe ROP, were elevated at the time when ROP first was detected but not at the time when current treatment most often occurred. This supports the need for further studies of circulating VEGF in relation to the timing of ROP treatment.
Authors: L E Smith; E Wesolowski; A McLellan; S K Kostyk; R D'Amato; R Sullivan; P A D'Amore Journal: Invest Ophthalmol Vis Sci Date: 1994-01 Impact factor: 4.799
Authors: Jie Ma; Manisha Mehta; Godfrey Lam; Desireé Cyr; Tat Fong Ng; Tatsuo Hirose; Khaled A Tawansy; Andrew W Taylor; Kameran Lashkari Journal: Mol Vis Date: 2014-06-21 Impact factor: 2.367
Authors: Luz Consuelo Zepeda-Romero; Miguel Vazquez-Membrillo; Elva Adan-Castro; Francisco Gomez-Aguayo; Jose Alfonso Gutierrez-Padilla; Eusebio Angulo-Castellanos; Juan Carlos Barrera de Leon; Cesareo Gonzalez-Bernal; Manuel Alejandro Quezada-Chalita; Alonso Meza-Anguiano; Nundehui Diaz-Lezama; Gonzalo Martinez de la Escalera; Jakob Triebel; Carmen Clapp Journal: Pediatr Res Date: 2016-11-14 Impact factor: 3.756
Authors: Sang Jin Kim; Alexander D Port; Ryan Swan; J Peter Campbell; R V Paul Chan; Michael F Chiang Journal: Surv Ophthalmol Date: 2018-04-19 Impact factor: 6.048
Authors: M Elizabeth Hartnett; David K Wallace; Trevano W Dean; Zhuokai Li; Charline S Boente; Eniolami O Dosunmu; Sharon F Freedman; Richard P Golden; Lingkun Kong; S Grace Prakalapakorn; Michael X Repka; Lois E Smith; Haibo Wang; Raymond T Kraker; Susan A Cotter; Jonathan M Holmes Journal: JAMA Ophthalmol Date: 2022-04-01 Impact factor: 8.253
Authors: Mariane Bertagnolli; Thuy Mai Luu; Adam James Lewandowski; Paul Leeson; Anne Monique Nuyt Journal: Curr Hypertens Rep Date: 2016-04 Impact factor: 5.369